Eli Lilly Gross Profit 2010-2022 | LLY

Eli Lilly annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Eli Lilly gross profit for the quarter ending March 31, 2022 was $5.738B, a 16.46% increase year-over-year.
  • Eli Lilly gross profit for the twelve months ending March 31, 2022 was $21.817B, a 12.81% increase year-over-year.
  • Eli Lilly annual gross profit for 2021 was $21.006B, a 10.23% increase from 2020.
  • Eli Lilly annual gross profit for 2020 was $19.057B, a 8.29% increase from 2019.
  • Eli Lilly annual gross profit for 2019 was $17.598B, a 4.68% increase from 2018.
Eli Lilly Annual Gross Profit
(Millions of US $)
2021 $21,006
2020 $19,057
2019 $17,598
2018 $16,812
2017 $15,526
2016 $15,512
2015 $14,922
2014 $14,683
2013 $18,205
2012 $17,807
2011 $19,219
2010 $18,710
2009 $17,589
Eli Lilly Quarterly Gross Profit
(Millions of US $)
2022-03-31 $5,738
2021-12-31 $5,950
2021-09-30 $5,342
2021-06-30 $4,787
2021-03-31 $4,927
2020-12-31 $5,720
2020-09-30 $4,414
2020-06-30 $4,277
2020-03-31 $4,645
2019-12-31 $4,831
2019-09-30 $4,302
2019-06-30 $4,512
2019-03-31 $3,954
2018-12-31 $4,508
2018-09-30 $4,154
2018-06-30 $4,351
2018-03-31 $3,799
2017-12-31 $3,321
2017-09-30 $4,072
2017-06-30 $4,253
2017-03-31 $3,880
2016-12-31 $4,239
2016-09-30 $3,791
2016-06-30 $3,940
2016-03-31 $3,542
2015-12-31 $3,986
2015-09-30 $3,723
2015-06-30 $3,760
2015-03-31 $3,452
2014-12-31 $3,868
2014-09-30 $3,609
2014-06-30 $3,746
2014-03-31 $3,460
2013-12-31 $4,422
2013-09-30 $4,575
2013-06-30 $4,765
2013-03-31 $4,444
2012-12-31 $4,709
2012-09-30 $4,240
2012-06-30 $4,454
2012-03-31 $4,404
2011-12-31 $4,725
2011-09-30 $4,810
2011-06-30 $5,025
2011-03-31 $4,659
2010-12-31 $4,955
2010-09-30 $4,667
2010-06-30 $4,725
2010-03-31 $4,363
2009-12-31 $4,503
2009-09-30 $4,510
2009-06-30 $4,345
2009-03-31 $4,231
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $284.459B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $468.600B 18.02
Pfizer (PFE) United States $284.304B 9.92
AbbVie (ABBV) United States $274.733B 12.04
Merck (MRK) United States $233.459B 13.19
Novartis AG (NVS) Switzerland $196.408B 14.14
GlaxoSmithKline (GSK) United Kingdom $112.779B 13.17
Novo Nordisk (NVO) Denmark $0.000B 30.73